Halozyme Therapeutics, Inc. entered a global collaboration and license agreement with AbbVie to develop and commercialize products combining AbbVie compounds with Halozyme’s ENHANZE platform. Halozyme will receive $23 million upfront and milestone payments totaling approximately $130 million for as many as nine collaboration targets, as well as royalties if products under the collaboration are commercialized. The Halozyme ENHANZE platform is based on a recombinant human hyaluronidase en...